Quantum News
Sign InSign Up
Back to News
research

Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Camurus reported strong Q4 2025 growth, driven by its opioid dependence therapies Buvidal and Brixadi, solidifying its global leadership in long-acting treatments for chronic illnesses. The company is expanding into the U.S. market, preparing for upcoming product launches while maintaining commercial operations in Europe and Australia. CEO Fredrik Tiberg highlighted FluidCrystal technology as the core innovation behind their long-acting drug delivery systems, emphasizing its competitive edge. Financial results showed continued revenue growth, with CFO Anders Vadsholt noting robust demand and strategic investments in R&D to fuel future pipeline development. Analysts focused on U.S. market entry timelines, commercial scalability, and R&D milestones during the Q&A, signaling investor confidence in Camurus’ expansion strategy.
AI Audio Summary
0:00 / 0:00
Click to play
2205e6bb-8ca1-4235-b162-5b07d4b8a3a2.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.36K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call February 12, 2026 8:00 AM EST Company Participants Fredrik Tiberg - President, CEO, CSO & DirectorAnders Vadsholt - Chief Financial OfficerRichard Jameson - Chief Commercial OfficerMarkus Johnsson Conference Call Participants Romy O'Connor - Van Lanschot Kempen NVGonzalo Artiach Castanon - Danske Bank A/S, Research DivisionPauline HendricksonChristopher Uhde - SEB, Research DivisionViktor Sundberg - Nordea Markets, Research DivisionOscar Haffen Lamm - Stifel, Nicolaus & Company, Incorporated, Research DivisionGeorg Tigalonov-Bjerke - ABG Sundal Collier Holding ASA, Research DivisionDan Akschuti - Pareto Securities AS, Research DivisionMattias Häggblom - Handelsbanken Capital Markets AB, Research DivisionErik HultgårdShan Hama - Jefferies LLC, Research Division Presentation Operator Welcome to Camurus' Q4 Report 2025. [Operator Instructions] Now I'll hand the conference over to CEO, Fred Tiberg. Please go ahead. Fredrik TibergPresident, CEO, CSO & Director Thank you, Einar, and hello, everyone. Welcome to our fourth quarter earnings call and full year. As customary, please note our forward-looking statements, which I will assume that you have read. So moving over to the agenda, we will begin today's call with an introduction and business highlights, followed by financial, commercial, and R&D pipeline reviews before finishing off with the key takeaways and Q&A. With me in the call today is Anders Vadsholt, Chief Financial Officer; and Richard Jameson, Chief Commercial Officer. So a quick overview of Camurus. We are a rapidly growing commercial stage biopharmaceutical company focused on developing and delivering innovative long-acting treatments for people living with serious and chronic illnesses. We have become a global leader in opioid dependence therapy with our products, Buvidal and Brixadi. Our commercial reach covers Europe and Australia, and we are now expanding into the U.S. as we gear up for upcoming product launches. At the core of our offerings is the FluidCrystal

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.